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Raman Spectroscopy, a form of vibrational spectroscopy, has the ability to provide sensitive 
and specific biochemical analysis of tissue. This review article provides an in- depth analysis 
of the suitability of different Raman Spectroscopy techniques in providing intra-operative 
margin analysis in a range of solid tumour pathologies.  
Surgical excision remains the primary treatment of a number of solid organ cancers. 
Incomplete excision of a tumour and positive margins on histopathological analysis is 
associated with a worse prognosis, the need for adjuvant therapies with significant side 
effects and a resulting financial burden. The provision of intra-operative margin analysis of 
surgically excised tumour specimens would be beneficial for a number of pathologies, as 
there are no widely adopted and accurate methods of margin analysis, beyond histopathology.  
The limitations of Raman spectroscopic studies to date are discussed and future work 
necessary to enable translation to clinical use is identified. We conclude that, although there 
remain a number of challenges in translating current techniques into a clinically effective 
tool, studies so far demonstrate that Raman Spectroscopy has the attributes to successfully 





New cancer cases continue to rise annually worldwide and are the second leading cause of 
mortality after heart disease, and account for 28% of all UK deaths 
1
 and 23% of all US 
deaths 
2
 and poses a major societal and financial cost to public healthcare systems that is 
predicted to continue to rise 
3
. Surgical excision of the primary tumour remains the primary 




The aim of cancer surgery is to remove the smallest amount of tissue necessary to 
minimise tissue trauma and collateral structural damage, whilst excising the entirety of the 
diseased tissue 
4
. This requires the affected tissue to be excised with a rim of normal tissue 
with an adequate or a ‘margin’. The amount of margin, or distance from the cancerous tissue 
to the edge of the specimen, required to be termed ‘clear’ is different for each pathology. If 
there is cancerous tissue within the defined distance from the resected surface, it is a Having 
a margin that has cancerous tissue in it, or a ‘positive’ margin and is defined as an inadequate 
resection, and which increases the risk of recurrence 
5-7
 (see Figure 1).  A positive margin not 
only affects prognosis, but also future management, meaning the need for further operations 
or adjuvant therapies with significant side effects. The cost of a positive surgical margin to 
the patient, in terms of increased treatment burden, further anxiety and additional side effects 
is difficult to quantify but the effect on the financial resources of the healthcare provider is 
undoubtedly significant 
8, 9
. A method to assess the margins of the excised specimen intra-
operatively to allow further tissue to be taken at the time of the initial procedure, if possible 
or necessary would be efficient, could reduce the risk of residual cancer at the end of the 
operation and improve patient care. 
 
Current methods of margin analysis 
The ‘gold standard’ method for analysis of resection margins of surgically excised specimens 
is currently histopathology. Histopathology analysis of prepared, ex vivo, tissue is conducted 
with light microscopy by trained physicians and is able to provide a detailed analysis of the 
excised specimen and the biochemical characteristics of the tumour, which contributes to 
clinical management decisions. However, the ‘gold standard’ of histopathology is prone to 
errors although it is likely underreported; one study found an error rate of up to 11% in 
cancer diagnosis 
10




Comment [HT1]: Careful with 
definint he word margin. 
Re-define with clarity here and check 
throughout. E.g. not ‘having a margin’, 
but ‘having a resected surface where 




, and even variability in the final diagnosis 
13
. This is even more apparent when 




Histopathology analysis of surgical margins may also be subject to errors. Even small 
specimens of around 2 cm across would require an impractical  number of histological 
sections if the entire resected margin surface was to be examined for adequate margins, and 
so margin assessment should be seen as a representative sampling procedure 
15
. The process 
also requires a number of steps which introduce sampling error - orientation by the surgeon, 
fixation to preserve the specimen, labelling the specimen, transportation to the pathology 
department, re-orientation by the pathologist, slicing the specimen, dehydration, embedding, 
sectioning, staining, representative sampling and then subjective assessment by 
histopathologists 
16-18
. In addition to this, the lack of real-time reporting delays treatment 
decision making meaning histopathology is an imperfect technique for the reporting of 
margins. This precludes any removal of further, possibly cancerous, tissue without the need 
for a second, often more difficult, operation. In many pathologies, the risk of a second 
operation outweighs the benefits of the risk of recurrence, and so in cases of a positive 
resection margin, potentially cancerous tissue remains 
19, 20
. It is possible that the concept of 
requiring a defined margin for surgically excised specimens is a result of the current inability 
to check the entire surface margin, and that if a technique could accurately assess a specimen, 
smaller, or no, margin distances would be required. 
 
Methods of Intra-operative Margin Analysis (IMA) 
Recognising these limitations of the traditional model, there has been a rapid increase in theis 
a large body of research investigating methods of IMA. Current and prospective methods of 





practical way of avoiding surgical artefacts such as blood contamination and the space 
constraints of in vivo analysis. Although it could be postulated that in vivo analysis of a 
tumour margin bed or lymph node could be advantageous, the reality of a contaminated field 
due to other structures and blood mean that ex vivo analysis of the excised specimen is the 
most realistic way this can be achieved.  The number of methods being investigated is vast, 
what follows is an overview of more established techniques that have had routine clinical 
application, though not necessarily widespread adoption.  
 
A commonly used method in cancer surgery is frozen section analysis. The specimen is 
transferred to the pathology department, frozen and sections of interest taken for analysis by a 
pathologist. It is a technically difficult procedure, requiring a histopathologist to be available 
on demand, a turnaround time that can impede surgical workflow, the processing can damage 
specimens which require further histopathological examination and it is expensive 
21
. Frozen 
section is most successfully used in Moh’s micrographic surgery in the treatment of Basal 
Cell Carcinoma (BCC) of the skin, where the entire resected surface is examined in 
horizontal sections intra-operatively and the surgeon continues to excise tissue until the 
margin is clear. Recurrence rates are as low as 1-3% even in recurrent and complex disease 
22
. However due to cost and time issues it is reserved for cosmetically sensitive areas and 
recurrent BCC.  Frozen section is used widely in head and neck cancers 
23
 however there is a 
significant number of false negatives 
23
 and it is unreliable for eradicating positive final 
margins 
24
. The technique has also been used for IMA in breast cancer excision (where there 
is reported sensitivity 70-90% and specificity 80-90%
25, 26
)  and radical prostatectomy (with a 
poor sensitivity of 42%
27





In Breast cancer surgery the technique has been reported as 
having sensitivity between 70 - 90% and specificity of 80- >90% 
22, 23
 however it has not 
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been adopted as standard care as it may not be cost-effective 
25
. In the diagnosis of margins 
for radical prostatectomy, in one study the sensitivity was only 42% 
24
, and a subsequent 
meta-analysis concluded that the sensitivity and specificity of frozen section meant the 
technique was of limited clinical value 
24, 26
. In head and neck cancers frozen sectioning is 
widely used to determine tumour bed margins, however the precise method varies between 
surgeons 
28
. The concordance of frozen section analysis with final histopathological diagnosis 
is reasonable but there can be a significant number of false negatives 
27
 and it is unreliable for 




Intraoperative imprint cytology has shown promise in Breast surgery. A slide is pressed onto 
the lumpectomy margin resected surface and analysed by a pathologist for malignant cells, 
which can be reported within the time frame of an operation. Issues identified with the 
technique are that slide preparation can affect the outcome, it is less accurate in lobular 
carcinoma
30
 and in tissue that has been subject to previous radiotherapy 
31
, and it reports only 
on the resected surface, not the entire margin depth.  In aA meta-analysis of eleven studies it 
has shown goodrevealed a pooled sensitivity of 91% and specificity 95% 
32
,. hHowever, 
despite this, inin clinical trials the need for delayed re-excision remained disappointingly high 
one study the intra-operative excision rate was high at 38%, and the delayed re-excision rate 
after formal histopathological analysis remained at 13% 
30
 suggesting this may not translate 
into improved clinical practice. Issues identified with the technique are that slide preparation 
can affect the outcome, the technique is less accurate in lobular carcinoma
31
 and in tissue that 
has been subject to previous radiotherapy 
32
, and, as a surface technique, it only reports on 
involved margins, not close margins.  
Touch imprint cytology has been used to assess the staple lines of resected specimens in 
pulmonary excision for non-small cell lung cancer to inform the extent of resection 
33
 and for 




, and has been shown to have 83% accuracy in assessing the 
margins of oral squamous cell carcinoma resection specimens 
35
, but has not been utilised in 
intraoperative decision making for these pathologies.  
 
Intra-operative imaging to assess margins has been used in various pathologies.  
In breast surgery the most common adjunct in the UK to analyse margins is an intraoperative 
specimen X – ray to determine how close radio-opaque lesions are to the edge of the sample. 
It was is used by 96% of UK units who responded to one survey 
33
, as this it is readily 
available and requires no additional equipment. However, for margin analysis it was shown 




Intraoperative ultrasound has also been used to guide lumpectomy in breast conserving 
surgery, but margin assessment was associated with a high false positive and false negative 
rate 
34
 and poor sensitivity 
35
. However, in one study the outcomes appeared favourable, as 
although there was a high false positive rate of 76%, there was a low second operation re-
excision rate of 4%, with an acceptable total specimen weight
36
. In brain lesions, 
intraoperative US has been seen as useful to guide excision, however there is a high degree of 
user variability and has been associated with a high rate of false positives possibly due to 
blood artefacts such as blood which also appears asis also hyperechoic 
36
. 
Magnetic Resonance Imaging (MRI) is used extensively in the planning of brain cancer 
surgery and is used intra-operatively to guide excision. In a randomised controlled trial, with 
a small population of 58 patients, the intra-operative use of MRI was associated with 
complete tumour resection 
37
. However, an issue is ‘brain-shift’ where loss of cerebrospinal 
fluid and oedema changes the anatomy and so reduces the accuracy of neuronavigation 
38
 and 





The sheer number of techniques proposed for IMA demonstrates that no single method has 
proved to be accurate, quick, reproducible, available or cost effective enough to be accepted 
into routine clinical practice. The ideal method for analysing excised tissue would be 
sensitive, specific, not alter the specimen (to allow subsequent histopathological analysis), 
recordable to allow accountability, give a definitive answer which is easily understood 
without the need for specialist training, and processes the sample without delaying surgery. 
The tool to deliver the analysis should be portable to allow use in multiple locations, robust to 




To address this gap in surgical care, n Novel optical techniques show promise as they can 
provide sensitive and specific biochemical information at a molecular level in a rapid and 
non- destructive manner. A number of microscopy techniques, such as Microscopy with UV 
surface excitation (MUSE), and light sheet microscopy, show the ability to differentiate 
between cancerous and non-cancerous tissue but studies so far have been limited in sample 
size and to physically small samples due to speed of analysis, which limits the conclusions as 




. Other optical techniques have struggled to succesfully translate 
promising laboratory work into the clinical environment, such as oOptical coherence 
tomography (OCT) which was found to have reduced effectiveness when it encountered 
cauterised tissue and blood 
42
, and a clinical trial in breast specimens demonstrated it only 
identified 63% of those with a positive margin
43
. Diffuse optical spectroscopy has the 
potential to provide excellent sensitivity and specificity in cancer diagnosis
44
, but so far this 
has not been realised in the analysis of margins
45
.  , Raman Spectroscopy (RS) is a technique 
of vibrational spectroscopy that has gained particular momentum as it can provide detailed 





surgical environment in human tissue in a range of pathologies. RS has the potential to 
change the paradigm of oncological surgery and provide IMA; an idealised surgical 
workflow of this is suggested in with a rapidly increasing volume of literature of its clinical 
application to margin analysis, which is the subject of this review (see Figure 2). 
 
Raman spectroscopy  
RS was first described by C.V. Raman in 1928 for which he was subsequently awarded the 
Nobel Prize 
41
. It is a mode of vibrational spectroscopy measuring the inelastic photon 
scattering after it has interacted with a molecule 
46
. To acquire this information, Aan incident 
source of photons (commonly a laser to provide a intense monochromatic light) is directed at 
the molecule(s) to be analysed. The majority of interactions result in a transient molecular 
vibration at the incident photon’s frequency and a re-emission of a photon of equal frequency 
to the incident photon. A small fraction of interactions lead to inelastic scattering, resulting in 
differences in energy between the incident photon and the scattered photon. This can be a 
gain or loss of energy, it is dependent on the inherent vibrational modes of movement a 
molecule has which is a product of its atoms and bonds, resulting in each molecule producing 
a unique Raman spectrum, or ‘fingerprint’
47
.  
The light collection system splits the light into its constituent frequency and provides the 
information on the intensity at each shift in energy (or frequency) from the laser line. The 
fingerprint spectrum of a tissue can be analysed and compared to established reference 
spectra to elucidate its biochemical composition; such as nucleic acids, proteins, lipids and 
carbohydrates, or the relative differences between spectra can be used to differentiate 
between tissues 
48, 49
.  Although highly specific, Raman scattering is considered weak, with 




of total scattered photons, which has 
initially limited its clinical application. However, recent advances in instrumentation, such as 
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 10 
filters to reject the elastically scattered photons, CCD cameras and cheaper, portable laser 
sources are enabling this challenge to be overcome. The molecular specificity of the Raman 
spectrum is holding great promise in medical diagnostics 
50
, and. a 
 
A variety of RS techniques have been developed in response to different needs. What follows 




This technique combines Raman spectroscopes with optical microscopes, allowing for 
analysis of sub millimetre specimens, such as histological slides 
51
. The tissue is scanned 
using raster scanning (point by point) and then uni- or multivariate analysis is performed to 
analyse the resulting Raman spectrum. This is point scanning, which iswhich is time 
consuming as each point measurement can cover as little as 300-500 nm across and so 
processing a sample can potentially take, many hours. Line scanning (changing the size of the 
incident beam to a line across the sample), and multi-focal Raman microspectroscopy 
(dividing the incident laser into several beams to measure multiple Raman spectra 
simultaneously) can reduce the analysis time to more clinically relevant times 
52-54
. Wide-
field global imaging techniques, where the whole sample is illuminated and all spectra 
associated with a particular wavelength are collected can also decrease analysis times, but flat 
field illumination can be difficult and this reduces the laser power per pixel, unless a very 




A further method to increase the speed of analysis is to reduce the number of Raman spectra 
taken for measurement by highlighting targeted areas for intensive raster scanning, in 
Formatted: Not Highlight
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selective scanning Raman microscopy 
56
. This can be performed by predictive algorithm, 
where spectra are taken at two random points on the sample, and the difference between the 
spectra informs an algorithm to predict where to take the next measurement 
56
. Another 
method is to use another, less specific, but highly sensitive optical technique such as auto-
fluorescence to rapidly assess the sample and determine where to take Raman spectra 
57
. This 
allows a substantial reduction in the number of Raman spectra taken, with a similar 
diagnostic yield, and in a shorter time period. These techniques have been assessed in 
melanoma excision surgery, both with a substantial reduction in spectra taken, sample 
processing in less than an hour and with excellent sensitivity and specificity 
52
.  
Surface Enhanced Raman Spectroscopy (SERS) 
SERS is a method to enhance the inherently weak Raman scattering by using receptor 
targeted metallic nanoparticles combined with bright Raman reporter molecules as 
biomarkers. Nanoparticles bind to the tissues of interest in a specific configuration and ratio 
that gives a unique spectrum. These nanoparticles give an intense signal due to their 
brightness and specificity, and so a large area can be rapidly scanned to give a reliably 
sensitive and specific Raman Spectrum 
58
. However, the obvious disadvantage lies in the time 
needed for pre-processing of samples with nanoparticles, and the potential risk of toxicity of 
metallic nanoparticles that may limit its in vivo use 
59
. The inherent heterogeneity of tumour 
biochemistry and receptor expression both within and between patients can affect the 
accuracy of these techniques 
60
. 
SERS with topically applied nanoparticles have been used in the diagnosis of Breast 
pathology and validated against flow cytometry and immunohistochemistry 
55
 before being 
used on 57 ex vivo fresh tissue samples, with a 89% sensitivity and 92% specificity of 
identifying cancerous tissue within 15 minutes 
56
. The use of this technique to guide the 
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 12 
assessment of margins in lumpectomy samples, and the logistical difficulties inherent in 
processing samples intra-operatively, has yet to be assessed. 
 
Spatially Offset Raman Spectroscopy (SORS) 
The previous techniques are restricted to analysing the surface of the cut tissue, as 
illumination and collection take place in the same location. SORS can provide biochemical 







, rectal cancer 
57
, anal cancer 
58
 and cervical cancer 
59
; a cancer 
within millimetres of a margin is associated with an increased risk of recurrence and may 
prompt further tissue excision, and therefore information below the cut surface is required to 
inform intra-operative decision making.  SORS illuminates at a central point then collects 
scattered data at a distance from this central point, the light having travelled through varying 
depths of tissue. In using multi-variate analysis of the resultant spectra, the offset between 
illumination and collection is accounted for, and a depth profile of the tissue with tissue 
information can be gained 
61
. An essential component of this technique is that it ameliorates 
interference by the often- stronger Raman scattering and fluorescence from the tissue surface 
to be able to analyse the tissue below. The configuration of the laser illumination centrally 




SORS has been used in in vivo rat models to assess the incorporation of bone allografts in rat 
tibia 
62
, and in the healing process after burn injury 
63
. In our labs we have various 
demonstrations of in vivo SORS systems able to measure skin layers and bone composition in 
1 second 
64
. Although not direct clinical applications, it demonstrates the potential of SORS 
to provide non-invasive transcutaneous information.  
 13 
Keller et al used a SORS probe that was initially validated in phantom models prior to the 
detection of breast cancer to assess margins in ex vivo breast cancer specimens 
65
, the 
limitations of which are discussed later.  
Transmission Raman Spectroscopy (TRS) is an extreme version of SORS, where incident 
beam and collecting camera are opposite one another, to allow analysis through the sample to 





High Wave Number (HWVN) Raman Spectroscopy 
RS can be measured with fibre optic probes which opens the way to numerous clinical 
applications and can be used within already available commercial devices such as a 
hypodermic needle 
58
 core needle biopsy system 
59
 and endoscopes 
60
 ( see Figure 3.).  
The majority of biomedical RS uses Near Infra-Red (NIR) light to acquire spectra within the 
‘Finger Print’ (FP) region of 400-1800 cm
-1
 which has been shown to provide extensive 
detail of the tissue biochemistry. However, when this laser light illuminates the fused-silica 
fibre required for fibre optic probes it generates an intense background signal 
64
. Using the 
HWVN region of 2400-3800 cm
-1
 to gain data from a fibre optic can allow Raman spectra to 
be collected without this background interference 
64
. RS can be measured with fibre optic 
probes whichThis opens the way to numerous clinical applications and can be used within 
already available commercially available devices such as a hypodermic needle 
65
 core needle 
biopsy system 
66
 and endoscopes 
67
 ( see Figure 3.). Thise advantage gained in the small size 
of the probe and flexibility must be weighed against the disadvantage of using spectra in the 
HWVN region spectra, which is less specific and may have limited diagnostic capabilities 







Coherent anti – Stokes Raman scattering (CARS) and stimulated Raman spectroscopy (SRS) 
CARS and SRS are non- linear processes, where the observed effect is not linear to the 
incident laser power, as it is a result of multiple overlapping photons. It can therefore 
generate a signal intensity greater than coherent Raman. By probing specific, narrow spectra 
with high intensity, specific molecular information can be gained rapidly 
69
. A CARS image 
is the result of the interactions of three photons, the pump, probe and Stokes photon. The 
targeted molecule groups will vibrate coherently if the difference in energy between the 
pump and the Stokes photon equals the energy of a molecular vibration 
70
. The probe photon 
then interacts with this oscillation and an anti-Stokes photon is produced at a new frequency 
which is detected and produces a CARS image. The advantages of CARS relate to its 
sensitivity to CH molecules making it particularly effective at studying lipid and fat 
distributions, which can been performed at video rate of 100 ns per pixel 
70
. However it is a 
near surface technique and interpretation is made difficult by the presence of a non-resonant 
background, causing spectral distortion and artefact 
69, 71
.  
A SRS signal is generated when the molecular vibration is equal to the difference in 
frequency between the pump and Stokes photon. The change in intensity of these beams as a 
result is measured. Its use was previously limited by slow acquisition times and its reliance 
on back-scattering meant it was inherently weak. However, new techniques have overcome 
these issues and allowed rapid acquisition of spectra to give detailed biochemical information 
71
. Further, SRS is non-resonant background free, can be performed with ambient light 




The ability of these techniques to differentiate lipid content has shown particular promise in 




Spectroscopic Data Analysis 
 15 
Regardless of the method of Raman spectroscopy utilised to gain spectra, the raw spectra 
require careful analysis to elucidate clinically relevant information. Differences between 
tissue spectra, although highly specific and holding detailed chemical information, can be 
subtle. In the setting of intraoperative margin analysisIMA, data analysis is focused on 
providing a binary outcome of whether the margin is clear adequate or not.  
In general, there will be a ‘training set’, which are spectra assigned to known tissue 
correlations i.e. a spectrum taken from tissue which has a histopathological diagnosis (as 
demonstrated in Figure 4). These are used to create a model, which is then tested on a 
‘validation set’, where the diagnostic accuracy can be assessed. This training – validation can 
be run multiple times with a Leave One Out Cross Validation (LOOCV) protocol to provide a 
measure of independence in the performance measures 
73
. 
The types of mathematical models used to create spectral classifications are numerous, and 
expanding. A simple technique is Direct Peak Analysis – where individual spectral features 
are analysed e.g. the areas under an individual Raman band  can be compared 
74
. Principal 
Component Analysis (PCA) and Cluster analysis are unsupervised techniques, that do not 
require assignation of spectral peaks, but identify where in the spectrum the greatest variance 
between data lies and classifies data according to these groups. Linear Discriminant Analysis 
(LDA) is a supervised technique that is commonly used to distinguish differences in the 
classes identified by PCA to increase accuracy. Increasingly complex models have been 
developed such as Support Vector Machines (SVM) and Random Forest Classifiers 
75
 and 
can improve diagnostic accuracy
76
, however they can be more difficult to apply and interpret. 
The machine learning classifier used to analyse spectral data is an important part of system 
development. The balance between simplicity and speed of simpler techniques versus the 
complexity and improved accuracy of more recent models needs to be considered when 




The use of RS to determine the surgical margin 
Breast Cancer 
Breast cancer holds great potential for intra-operative use of RS, with a number of groups 
reporting a variety of advanced techniques to assess the margins of lumpectomy specimens.  
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For the majority of patients with early primary breast cancer, Breast Conserving Surgery 
(BCS) (with adjuvant radiotherapy) offers an alternative treatment to traditional Mastectomy, 
with equivocal survival rates and improved patient satisfaction (Fisher, 1985). In Breast 
conserving surgery, the cancer is removed from the breast, termed a lumpectomy. The 
method of assessing margins are currently mainly by surgeon palpation, if it is a palpable 
lump, or radiographically with an intraoperative X - ray. Neither are a reliable way of 
assessing the specimen for involved or close margins 
77
, and as a result, the rate of close or 
involved margins is high 
33
.  
The definition of a positive margin is most commonly described as ‘ink on the tumour’ 
78, 79
, 
the definition of a ‘close’ margin is much more debated, however in the UK it is defined as < 
2mm, however, the resultant practice as to whether a re-excision of margins is recommended, 
or indeed undertaken, is much more variable 
33
. A positive margin is associated with a 2 fold 
increase risk of local recurrence, despite adjuvant therapies 
80
. Therefore, a positive margin, 
and more variably, a close margin usually necessitates a re-excision of margins. This is a 
further operation where the operation site is re-opened and the tumour bed examined, the 
surgeon then takes a further 1 cm rim of breast tissue at the margin site that was reported as 
involved. The number of cases requiring re-excision is high, with a UK average of 17% and 
some units reporting up to 38-41% 
30, 33
. The steps involved in this re-excision are numerous 
and complex and the sheer volume is a significant financial burden.  
 
RS ability to differentiate normal from abnormal breast tissue 
There is a large body of evidence confirming the ability of RS to differentiate between 
normal, benign and malignant changes. A meta-analysis included 9 studies and concluded 
that using RS in vitro in breast tissue to diagnose breast cancer gave a pooled sensitivity of 
 17 
0.92 and specificity of 0.97 
81
. However, there was a marked heterogeneity between study 
techniques, and so studies need to be considered individually.  
 
In 2005, Haka examined lumpectomy and mastectomy tissue from 58 patients that had been 
snap frozen then thawed. They used Raman micro-imaging to gain a sampled volume of 
1mm
3
, and determined a total of 130 spectra, which they used in a leave-one-out cross-
validation analysis. With this model they got a 94% sensitivity, 96% specificity and an 
overall accuracy of 86% for detecting infiltrating carcinoma. Fibroadenomas appeared to 
count for this diagnostic uncertainty; in 2 instances the Raman diagnosis was fibroadenoma, 
and the histopathological diagnosis was infiltrating carcinoma. The reason may have been the 




In a paper to compare the spectroscopic techniques of fluorescence, diffuse reflectance, 
combined fluorescence and diffuse reflectance and RS, in the diagnosis of Breast cancer, 
Majumder et al. found RS to be the most effective 
83
. They used 74 frozen – thawed 
specimens to measure 293 spectra with point RS. They found distinct peaks associated with 
connective tissue proteins and fatty acids discriminated well between normal tissue, 
fibroadenoma, invasive ductal carcinoma and DCIS being able to classify 99% of spectra 
correctly. This was done in laboratory conditions, and the area sampled was not reported, but 
can be presumed to be small. 
 
Barman et al developed a single step Support Vector Model algorithm using point RS to 
diagnose breast lesions from 33 patients undergoing Vacuum assisted biopsy, specifically in 
those with microcalcifications 
84
. They achieved an overall accuracy of 82% of diagnosis 
 18 
with excellent Positive Predictive Value (PPV) (the probability of a positive result being a 
true positive) of 100% and Negative Predictive Value (NPV) (the probability of a negative 
result being a true negative) of 95% for breast cancer. However, this was performed in 
physically small biopsy samples, with a selective population of tissue all with calcifications 
present, which are known to produce relatively intense Raman spectra 
85
, and thus may be 
unrepresentative of all breast cancers. 
Han et al used a confocal Raman system to look at freezing microtome sections of breast 
tissue 
86
. They defined the peak assignments of Raman spectra associated with breast tissue 
and found that the relative intensity of the C = O peaks increased with increasing grade of 
malignancy. They took 475 spectra from 39 patients and identified that there was little inter-
subject variation in the spectra. They used a Support Vector Model for their classification 
model and achieved an overall accuracy of 74%. 
 
An issue with these techniques is that they are surface techniques, so if there was cancerous 
tissue more than a few hundred microns from the surface this would not be detected, so 
‘close’ margins (which usually require excision) of up to 2 mm would go undetected. 
Spatially offset Raman spectroscopy (SORS) can resolve this and Keller et al developed a 
SORS probe that obtained spectra at a depth of 2 mm 
87
. In 35 samples of frozen- thawed 
tissue they attained sensitivity and specificity of >94%. They assessed the margins compared 
to histopathology as simply ‘positive’ or ‘negative’ rather than gaining specific tissue 
diagnosis. The sampling size of the probe, nor the method of location of tissue sampling is 
described, but the authors recognize that assessing the margins of an entire specimen in a 
clinically relevant time is a limitation of the technique. 
 
 19 
These studies were all done on micro or point spectroscopy, sampling very small areas of 
breast tissue to obtain Raman spectra. For application to IMA, it is necessary for a large area 
to be analysed, rapidly and so complimentary techniques have been applied to enable this. 
Kong et al used auto-fluorescence imaging to inform selective -sampling Raman microscopy 
to provide an accurate diagnosis within a clinically relevant time frame 
57
. Tissue samples cut 
from blocks that were frozen-thawed were used and sensitivity and specificity of >90% were 
achieved. An example of these microspectroscopy mapping results and assignation of spectra 
to tissue is shown in Figure 4. This study only differentiated between ductal carcinoma and 
normal tissue, and in other studies, it is DCIS and fibroadenomas that negatively affect the 
overall accuracy of the analysis. Once again, the breast tissue samples were small (5 X 5 
mm
2
), and so the conclusion of analysis within a clinically relevant time frame was 
extrapolated. How the technique would be applied to a whole specimen without cutting the 
sample is also unexplored. 
 
Intra-operative use of Raman spectroscopy 
Based on these promising initial results, the same groups went on to use RS in the clinical 
setting with the potential to give an intra-operative diagnosis. 
Haka et al used their previously validated technique in freshly excised tissue from 28 patients 
measuring 220 spectra 
88
. Tissue with Ductal carcinoma in situ was excluded, as the 
validating set had not encountered this pathology which is an important exclusion for intra-
operative use, as DCIS is associated with a higher rate of re-excision of margins 
89
. It also 
excluded patients having undergone neo-adjuvant chemotherapy, which is increasingly 
common, and those patients with calcifications. Once again, fibroadenoma proved a 
diagnostic challenge, and the positive predictive value of 36% can be considered poor, with 
an overall accuracy of 86%. Although the authors felt that the high NPV of 99% was the 
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main clinically relevant outcome, with such a low PPV in clinical use this would lead to a 
high volume of breast tissue unnecessarily being excised. The tissue area sampled is not 
mentioned, meaning the relevance of the technique to assessing an entire sample for margin 
adequacy is difficult to assess. 
Despite these limitations, this was performed adjacent to the operating room, in a light box, 
and analysis was performed in 30 minutes, recreating conditions necessary for intra-operative 
use of the technique. 
 
Wang et al used SERS with nanoparticles to assess 57 freshly excised lumpectomy 
specimens and processed samples within 15 minutes 
90
. Each specimen was topically stained 
with Raman active nanoparticles that were functionalised with antibodies to target HER2, 
mER, EGFR and CD44 and then raster-scanned to acquire spectra for the entire resected 
surfacemargin on the exposed glandular tissue. It was possible to differentiate between 
normal, benign changes and invasive carcinoma tissue, and the overall sensitivity for breast 
carcinoma detection was 89% with 92% specificity, with the accuracy for the specific 
biomarkers slightly less than this. This technique is not affected by haemoglobin, surgical 
dyes or diathermy increasing the clinical relevance, however, it is limited by the sensitivity 
and specificity of not only the functionalised nanoparticles ability to bind to the molecules of 
interest, but also the accuracy of the Raman signal of the nanoparticles.  Another limitation is 
that, as a surface technique, ‘close’ margins are not detected. 
 
Using a method of selective scanning, Shipp et al performed analysis on freshly excised 
lumpectomy samples from 51 patients, and analysed one resected surfacemargin of each 
specimen which was identified as being most likely to be positive by a member of the team 
91
. They used multimodal spectral histopathology (MSH), obtaining autofluorescence images, 
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which was highly sensitive but non-specific, to inform targeted Raman measurement points 
in identified ‘segments’ to reach a final diagnosis. The diagnostic algorithm was validated 
using a training set based on mastectomy samples which included tissue containing 
fibroadenoma, fibrocystic change, DCIS and invasive carcinoma. MSH in the lumpectomy 
samples was highly sensitive, identifying all the margins that contained residual cancer even 
as small as 1 X 1 mm
2
, and so was 100% sensitive, with around 80% specificity. They 
analysed a single margin resected surface of up to 4 X 6.5 cm
2
 in 12-24 minutes, which was 
achievable as MSH reduced the number of Raman spectra required by 100 – 200 fold. 
Although this study shows significant improvement in the speed of analysis and the 
diagnostic accuracy, there are some limitations in the way the lumpectomy specimens were 
subsequently examined, and that only one margin resected surface could be examined in a 




Skin cancer is the most common cancer diagnosed and its diagnosis and treatment represents 
a huge burden on the health economy 
92
. Basal Cell Carcinoma has the highest incidence and 
is predicted to rise. It is a slow growing tumour, that rarely metastasises, but local invasion 
leads to local tissue destruction and deformity. Surgery remains a treatment of BCC, the 
tumour can be excised by standard surgical excision where the lesion is excised with the aim 
of obtaining margins of 3 – 5 mm. A positive, or close margin has been reported in up to 7% 
of cases and is associated with a high recurrence rate of up to 27% 
93
 and requires further 
treatment or re-excision 
94
. Mohs’ micrographic surgery is another technique where the 
complete surgical margins are examined in horizontal sections intra-operatively and the 
surgeon continues to excise tissue until the margin is clear.a current technique used for IMA 
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but iIt is time consuming, and expensive and is only recommended in high risk cases such as 
large tumours in cosmetically sensitive sites, certain histological subtypes or recurrent BCC 
94, 95
.  
Melanoma is less prevalent than non-melanotic cancer but incidence is rapidly rising, it has 
metastatic potential and late presentation is associated with a very poor prognosis 
96
. The 
management of melanoma is based on surgical excision, with margins of 0.5 – 2 cm required 
based on the stage of disease, and re-excision performed if there are involved margins
97
. A 
margin narrower than this is an inadequate resection which increases the risk of recurrence 
associated with a poor prognosis, and may possibly be associated with worse survival 
98
. 
For both melanoma and nonmelanoma skin cancer, there is a need for IMA to improve 
patient outcome. 
 
RS ability to differentiate normal from abnormal skin tissue 
Confocal RS has beenwas first used to differentiateidentify  BCC from normal skin non- 
melanotic skin cancersin 2002, where Raman maps from a small sample of 15 specimens 
were taken and compared to surrounding normal tissue which yielded sensitivity and 
specificity of over 90% in a logistic regression model 
99
. Nijssen 
acknowledgedAcknowledging the practical limitations of previous studies in using confocal 
RS, the group acquiring spectra from the  FP region of 400 – 1800 cm 
-1
,used a handheld 
fibre optic probe and gained spectra using HWVN RS in the region of 2500 – 3800 cm 
-1 
to 
avoid background signal from silica
 100
. A number of readings from each of 19 biopsies taken 
from the centre of confirmed BCC’s were analysed, which demonstrated large and consistent 
differences between the spectra from BCC and normal tissue, particularly that collagen 







However, gaining spectra at this wavenumber region took longer due to suboptimal signal-to-




. These studies looked solely at BCC, whereas non-melanotic skin cancer also includes 
squamous cell carcinoma. Lieber et al analysedMeasurements were taken from 21 suspected 
non melanotic skin cancers and took measurements with confocal RS from within the tumour 
and compared to normal skin adjacent (1 cm distant) from the tumour margin edge at a depth 
of 20 µm 
101
. They achieved good sensitivity of 100% for determining the cancerous lesion 
and specificity of 91%, with squamous cell carcinoma lesions accounting for the diagnostic 
uncertainty. The sample population of 19 patients was small and although marked differences 
in Raman spectra were observed for each pathology this was after subtracting the matched 
normal reading. There is marked inter-subject variability in the Raman spectra of normal 
skin, and without a matched normal reading the diagnostic accuracy is likely to have been 
affected. The same group went on to perform measurements at varying depths on fresh-
frozen samples from 39 patients with no skin pathology, BCC, SCC or melanoma and 




Nijssen acknowledged the limitations of previous studies in acquiring spectra from the  FP 
region of 400 – 1800 cm 
-1
, and gained spectra using HWVN RS in the region of 2500 – 3800 
cm 
-1 102
. A number of readings from each of 19 biopsies taken from the centre of confirmed 
BCC’s were analysed, which demonstrated large and consistent differences between the 
spectra from BCC and normal tissue, particularly that collagen contains discriminative 
information at this wavelength, with a 100% diagnosis of BCC. However, gaining spectra at 
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this wavenumber region took longer due to suboptimal signal-to-noise ratio, which may limit 
its clinical use, and there was a small study size.  
 
Schleusener et al recruited 104 patients scheduled for excision of a suspicious lesion and 
used a fibre coupled probe in vivo with direct skin contact to sample 3 measurements on each 
lesion and the mean used to inform the spectra 
103
. The heterogeneity of the lesions led to 
poor accuracy in determining non-melanotic skin cancer from normal skin cancer. The major 
differences in skin variability between body site also contributed to the results that achieved 
an accuracy of 78% in discriminating BCC and SCC from normal skin. For melanotic lesions 
the lesion inhomogeneity was insignificant, and they achieved a balanced accuracy of 91% of 
differentiating melanoma from normal pigmented nevi. 
 
In aA largeer study, Lui et al investigated all skin cancerssuspicious skin lesions in vivo, both 
potential non-melanoma and melanomas, in 848 patients and acquired 1022 spectra 
104
. 
Spectra from the in vivo suspicious lesion were taken, and compared with then spectra from 
normal appearing skin 5 cm from the tumour edge were taken for comparison. The aim was 
to detect which lesions required invasive biopsy to histologically confirm malignancy which 
was achieved with 90% sensitivity and 64% specificity. The strength of this study was its 
clinical relevance – measurements were gained within 1 second, with a handheld probe, and 
was concerned with the relevant task of differentiating cancerous lesions from benign lesions, 
rather than from normal skin like other studies. However, the results were ultimately 
disappointing, with poor specificity. This may have been due to the heterogenous group of 
benign lesions to compare against (which didn’t necessarily have a confirmed 
histopathological diagnosis), and a relatively small number of malignant melanomas (n=44) 
Formatted: Not Highlight
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which may have underpowered the diagnostic algorithm.    The final diagnosis was confirmed 
by clinical evaluation or histological diagnosis if a biopsy was taken.  
The same group used a similar approach with a probe measuring a diameter of 3.5mm at a 
depth of 1mm to validate the previous diagnostic algorithm on a new cohort of 127 cases, 
where they achieved similar sensitivity and specificity in cancer versus non cancer diagnosis 
to the previous study
105
. It is noted that, setting the sensitivity level to 95%, only 8 of 9 
melanoma cases were correctly classified as a cancer, and the specificity was generally poor 
at 30 – 46% depending on the sensitivity level. The results are perhaps unsurprising as the 
diagnostic algorithm had previously had poor accuracy at melanoma diagnosis. 
 
 
In a meta -analysis to investigate the accuracy of RS for differentiating cancer from normal 
tissue, 12 studies using different methods of RS were included, then analysed according to ex 
vivo and in vivo studies and types of skin cancer. 10 of the studies investigated discrimination 
of BCC, and in vivo, the pooled sensitivity  for discriminating BCC from normal tissue 
samples was 69% and specificity 85%, compared to ex vivo sensitivity of 99% and specificity 
96% 
106
. This suggests the use of RS to examine ex vivo, resected cancer samples, for margin 
assessment may be a highly accurate technique. 
 
There are a number of studies investigating mixed methods of combining RS with other 
techniques to improve performance. Combining autofluorescence with RS, with six 
spectroscopic criteria, 79 ex vivo patient samples were analysed and cancerous tissue was 
classified with 97% accuracy 
107
. Another group used CARS, second harmonic generation 
and two- photon excited fluorescence imaging to analyse 140 ex vivo skin samples in a 
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multimodal approach that allowed large -area scans and the identification of dermal layering, 




Intra -operative use of Raman spectroscopy 
Kong et al used a method of measuring tissue autofluorescence to determine the sampling 
points for RS 
109
, a technique alluded to in the previous section 
110
. This MSH technique was 
used to analyse samples from 20 patients treated with Mohs’ microscopic surgery for BCC, 
half were BCC positive. Analysing tissue samples of up to 1 X 1 cm
2
 the sensitivity and 
specificity was 95% and 94% respectively for the detection of BCC within a time of under 60 
minutes. The same group has now reported a fully-automated prototype instrument based on 
this technique that allows assessment measurement of skin surgical resections of up to a 2 X 
2 cm
2
 area which detects residual tumour at the margin surface of the resected sample 
111
. 





Gliomas are tumours of the neuroglia graded by histopathological features that account for 
the majority of malignant brain tumours in adults. They have varying prognoses, but the 
commonest, glioblastoma multiforme accounts for 55% of all gliomas and has a 5 year 
prognosis of 5% with almost inevitable recurrence after treatment 
112
. Surgical resection is 
generally recommended as part of initial management for both histological diagnosis and to 
remove as much of the tumour as possible, if it is safe to do so 
113
. A major challenge of 
resectional surgery is achieving adequate margins, particularly as excessive tissue excision 
can lead to major neurological morbidity for the patient. With current imaging techniques of 
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neurosurgical microscopes or intraoperative MRI, even in cases of an apparently complete 
resection with ‘clear’ surgical margins, the vast majority of recurrences occur at the site of 




Improving the intra-operative assessment of surgical resection margins could improve 
adequacy of tumour resection, and thus recurrence rates for glioblastoma. 
 
RS ability to differentiate normal from abnormal brain tissue 
The majority of initial diagnostic work has been performed in mouse models of brain 
tumours. RS has been used to analyse tissue from mouse models of glioblastoma ex vivo and 
is able differentiate between normal tissue (white and grey matter) and malignant tissue with 
100% accuracy 
115
 and has been used to examine the tumour margins in mice in vivo, where 
RS identified tumour undetected by bright field microscopy 
116
. Uckerman et al used CARS 
to probe the C-H molecular vibration, thus imaging the lipid content of samples 
117
. A mouse 
model of glioblastoma was analysed ex vivo then the same technique used in human 
glioblastoma tissue to confirm the findings. They found malignant tissue was identified by a 
reduction in lower CARS signal intensity which was related to a lower content of total lipids 
in tumour tissue than normal tissue. This was at a cellular level and so tumour borders could 
be discerned precisely, the technique could gain images at 20 Hz, representing clinically 
relevant time for intra-operative use. 
 
Two studies using induced glioma formation in mice models have reported the use of 
systemically injected gold nanoparticles preferentially up- taken by tumour to inform SERS 
guided tumour resection 
118, 119
. The nanoparticles are hypothesised to cross the Blood Brain 
Barrier via low-density lipoprotein-receptor -related protein 1, an active transport endothelial 
Formatted: Not Highlight
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receptor that carries exogenous substrates across the BBB 
120
. The activation of the 
nanoparticles is then reliant on the acidic tumour environment, which results in a specific 
signal at the tumour site 
118
. A handheld Raman probe was used in both cases to demonstrate 
the delineated tumour margin and guide tumour excision. Although they show promise in 
mice models at assisting in obtaining clear excision margins, the translation of using a 
systemic agent in humans for diagnostic purposes only is likely to be complex and remains 
un-investigated. 
 
In human tissue, Raman microspectroscopy has been used to differentiate normal brain 
tissue, necrosis and brain metastasis and achieved accuracy of >95% 
121
.  Kalkanis et al used 
ex vivo human tissue from 17 donors to create histological slides from frozen samples. Within 
homogenous areas of normal, necrotic and glioblastoma areas a diagnostic accuracy of over 
97% was achieved in the validation group. However non-diagnostic areas, heterogenous areas 
and those with freeze artefact were excluded which limited sample size, and limits validity of 




Another clinically relevant study by Ji et al used Stimulated Raman Scattering (SRS) to 
examine tissue from 19 patients with CNS malignancy 
72
. They produced two- colour images 
based on the Raman intensity ratios which displayed whether the structure was lipid or 
protein-rich. Using biopsy samples, they asked pathologists to compare these SRS images 
with standard H+E pathology images and achieved excellent diagnostic concordance. This 
was carried out in standard lighting conditions. However, they acknowledge the areas 
sampled were much smaller than a true tumour bed, and SRS can only sample at a depth of 
100 µm. Furthermore, this approach is only likely to work when normal tissues are mostly 
lipid rich and the cancer or disease leads to a change in protein rich tissues. 
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Another group using SRS to analyse histology slides achieved similar results in 
differentiating between normal brain tissue and tissue containing a lesion. They used this to 
develop a machine learning process that was able to predict an automated diagnosis of 




Intra -operative use of Raman spectroscopy 
A recent study by Bury et al analysed 29 fresh brain tissue samples that had been excised 
during surgery within a clinically relevant time
124
. Using SERS, the samples were processed 
with gold nanoparticles and Raman spectra obtained, the tissue then underwent routine 
histopathological analysis. There were a number of diagnoses within the small sample size 
meaning it is likely to be statistically underpowered. Despite this they gained sensitivity and 
specificity above 75% in diagnosis of normal, glial and metastatic brain tumours, with 
meningiomas proving a diagnostic challenge with poorer accuracy. Results were comparable 
to currently used methods of IMA and superior diagnostic accuracy is needed for clinical 
adoption. However, this could be overcome by increasing sample size and measurements 
were taken in real time in a laboratory linked to the operating theatre via air-tube, which is an 
innovative solution to the often encountered problem of space, and demonstrates successful 
clinical application.  
 
In 2015 Jermyn et al reported the use of a handheld spectroscopy device that used a Raman 
fibre optic to perform sub-millimetre single point measurements of 0.2 mm
2
 in vivo in 
humans 
125
. 161 MRI guided intra-operative measurements were taken from 17 patients with 
gliomas, and a biopsy taken at the corresponding site for correlation of Raman spectra with 
H+E pathological diagnosis. They found specimens with cancer cells had a difference in the 
lipid bands, a higher nucleic acid content, and an increase in the band associated with the 
Formatted: Not Highlight
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breathing mode of phenylalanine in proteins. Tissue with cancer cells present were 
distinguished from normal brain tissue with an accuracy of 92%, which was significantly 
better than the operating surgeons’ visual analysis with a bright field microscope. This was 
performed intra-operatively with a small, hand held probe and measurements took less than 1 
second. The limitations related to the restricted field of view offered by the small area 
sampled by the probe, and the false negatives in the Raman analysis were due to the system 
needing > 15% cancer cell burden to be accurate.  
The same group then went on to integrate intrinsic fluorescence spectroscopy, diffuse 
reflectance spectroscopy and RS into one system to analyse biopsies taken from 15 patients 
with brain tumours of any type in a similar study design 
126
. Using this multimodal approach 
they achieved sensitivity of 100% and specificity of 93% in differentiating between normal 
brain tissue and tissue with cancer cells. 
This group have recently developed a probe incorporated within a commercially available 
biopsy system to allow Raman measurements to be taken without disrupting surgical 
workflow 
66
. It used HWVN RS to collect data mainly from lipids and proteins. It was 
successful at detecting normal brain tissue and dense cancer tissue but could not differentiate 
between normal brain tissue and tissue infiltrated with cancer- which is likely to represent the 
specimens with inadequate tumour resection margins of tumours. 
 
Head and Neck Cancer 
Background 
Head and neck squamous cell carcinoma (HNSCC) represent the main oncological burden of 
head and neck oncology. Resection remains the mainstay of treatment for the majority of 
HNSCC locations 
127
.  Complete resection of the tumour is the goal of surgical treatment, as a 




. Despite this goal, a significant proportion (30-65%) of HNSCC resections have 
positive resection margins 
129
. A pathologically involved or close margin affects further 
management which is often the use of adjuvant therapy such as chemotherapy and/or 
radiotherapy. Re-resection can be considered, but only if anatomical location allows and after 
associated morbidity is considered 
20, 130
. A common definition of a close margin is <5mm for 
HNSCC 
20, 131
. The Intra-operative technique for margin analysis has been frozen section 
which has been specimen or tumour – bed based, with variability in the way it is utilised, 
with no standard method adopted 
132
. However, there has been no convincing evidence that 




RS ability to differentiate normal from abnormal head and neck tissue 
The first report of RS to differentiate between normal and malignant larynx tissue was from 
Stone et al 
49
. Raman microspectroscopy was used on biopsies from 19 patients to 
differentiate homogenous samples of normal tissue from dysplastic and squamous cell 
carcinoma tissue. Diagnostic peak height ratios were used rather than absolute spectral peaks 
to inform a diagnostic prediction model that demonstrated sensitivity and specificity of >90% 
for the diagnosis of squamous cell carcinoma. 
Using frozen – thawed biopsy samples of vocal cord lesions, Lau et al analysed areas of 3.5 
mm within 5 seconds. There was heterogeneity of tissue type within measured samples which 
may have accounted for the reduced diagnostic sensitivity of 69% of detecting carcinoma 
134
.  
Lin et al developed a miniaturized RS fibre optic probe that was inserted down a working 
channel of nasendoscopy instrument to take measurements of suspicious laryngeal lesions in 
39 patients 
135
. The probe was put in contact with the lesion for < 1 sec prior to taking 
biopsies for histopathological analysis. They used the HWVN range (2800–3020 cm
−1
) to 
obtain 94 spectra and identified spectral peaks that successfully differentiated normal and 
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malignant tissue. In a similar experimental design in 60 patients, the same group used a 
combination of FP and HWVN RS to acquire over 2000 spectra and compared this to 
histopathological biopsy. They gained spectra rapidly in < 1 second, and the combined 
spectra yielded an overall diagnostic accuracy of 91.1% 
136
. The same group then acquired 
spectra from 90 patients with nasopharyngeal cancer and used PCA and LDA with a leave-




In the detection of oral carcinoma, Cals et al  took histological sections from 11 samples of 
oral SCC with surrounding normal tissue, and histopathological evaluation then selected the 
regions for RS measurements 
138
. Raman mapping with an automated confocal Raman 
microscope took point measurements at 5 µm steps to determine spectral differences between 
oral SCC and squamous epithelium, connective tissue, gland, muscle, adipose tissue and 
nerve. They achieved excellent distinction between SCC and healthy tissues with >97% 
accuracy. They went on to develop a two-step classification model using a similar 
experimental method for validation in 19 samples and achieved diagnostic accuracy of 91% 




In vivo detection of oral lesions was performed by Guze et al with a handheld probe in real 
time 
140
. The probe, which had disposable plastic sleeves, was used to diagnose lesions within 
5 minutes and the procedure was tolerated well by the 18 patients who had a previously 
known histological diagnosis of the oral lesion. They were able to differentiate between pre-
malignant and malignant tissue versus normal or benign lesions with 100% sensitivity and 
77% specificity.  
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The difference in water content between normal tissue and SCC has been used by one group 
as a marker to identify cancerous tissues in the head and neck. Using a confocal Raman 
microscope with HWVN RS at 2500 - 4000 cm
−1
 they used freshly excised oral SCC samples 
from 14 patients to take up to 30 spectra from each sample within 30 minutes and 
subsequently compared them to histopathological evaluation. They found the intensity of the 
OH-stretching vibration increased in SCC more than normal tissue, along with the water 
concentration being significantly higher in the SCC containing tissue. They concluded that 
water concentration could be determined with HWVN RS and was a useful diagnostic marker 
of SCC tumour 
74
. The group then used freshly resected oral SCC specimen sections 
containing both tumour and normal tissue to analyse how water concentration changes with 
distance from the tumour. Using a confocal Raman microscope at the same wavelength they 
then obtained over 3000 Raman spectra to determine that mean water concentration within 
the tumour was 76% and decreased further away from the tumour down to 54% when > 4mm 
from the tumour in healthy tissue
130
. A similar design was used in 26 mandibulectomy 
specimens and it was also found that water concentration is high within tumour (mean of 
77%) and decreases with distance from tumour to a mean of 44% in healthy tissue. These 
spectra were then used to develop a classification model for diagnosing SCC in bone in a 
training set and in the validation set achieved a sensitivity of 95% and specificity of 87% in 
tumour detection 
141
. They showed good diagnostic accuracy within clinically relevant times 
of less than 30 minutes. However, there are limitations to clinical applicability; the specimens 
had to be handled in a particular way to avoid desiccation, and these studies used cut 
specimens which may have different water properties to an uncut specimen. A flat surface 
was also necessary to achieve adequate contact with the Raman probe, which may not be 
achievable with a clinical specimen.  
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The data demonstrates a large inter-subject variation in water content in healthy tissue of 
17% in bone and 24% in mucosal tissue which suggests pathological tissue measurements 
would always need to be compared with concurrent ‘normal’ tissue readings 
141
. The 
calculation of water content for these measurements were based on a protein model and 
ignored the contribution of lipids to the measured spectral band. Although this is 
acknowledged and in oral mucosal tissue any high lipid signals were always associated with 
healthy tissue, this may not be the case with other tissues and so the ability to apply this 






The management of prostate cancer is based on a risk stratification composed of stage of 
disease, grade of disease by Gleason score and Prostate Specific Antigen reading. Radical 
prostatectomy is the surgical treatment of choice in men with intermediate or high risk 
prostate cancer 
143
. The balance of the oncological goal of achieving a complete resection 
with negative resection margins is countered by the functional goal of preserving the 
neurovascular bundle that controls erectile and continence functions and urethral length 
19
. 
There is a wide variation in the incidence of positive surgical margins reported in the 
literature (10-42%) 
144, 145
, a positive resection margin being defined as tumour at the inked 
edge of tissue 
146
. A positive resection margin is associated with an increased risk of 
biochemical and local recurrence and is an indication for additional treatment such as 
radiotherapy, which have functional side effects 
144, 147
. The extent of residual disease or 
extra-prostatic invasion can be difficult to discern intra-operatively and so IMA could 
improve oncological outcomes of patients undergoing radical prostatectomy.  
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RS ability to differentiate normal from abnormal prostate tissue 
The first study to differentiate benign prostatic hypertrophic (BPH) tissue using RS was 
performed in snap frozen core biopsy tissue, sampling around 30 cells in each spectrum. 
They evaluated the ability to differentiate between BPH and differing grades of prostate 
cancer, and demonstrated the best sensitivity (94%) and specificity (100%) in diagnosing 
high grade prostate cancer with a Gleason score >7 
148
. The biochemical basis for the 
differences observed were later elucidated by comparing a prostate tissue with a range of 
normal, benign changes and malignant prostate changes to known cell and tissue constituents. 





Aubertin et al analysed freshly excised specimens from radical prostatectomy of 32 patients 
with histologically confirmed prostate cancer 
150
. A section of the resected specimen thought 
most likely to contain cancer was taken and analysed at multiple points using a hand-held 
probe, gaining readings from the FP region of the spectrum and matched them to 
histopathological diagnosis. The exclusion criteria resulted in almost a quarter of spectra 
taken being disregarded for analysis, sample sizes for some grades of cancer were small, and 
only a small proportion of readings were from cancerous tissue (149 of 776), affecting 
interpretation of results. However, they achieved a sensitivity of 87% and specificity of 86% 
in differentiating benign from malignant tissue. 
The same group evaluated the diagnostic capabilities of RS by combining FP and HWVN RS 
in a separate study 
74
. Here they analysed sections from 18 prostate specimens to gain 477 
spectra from both regions and tested with Leave-One-Patient-Out-Cross-Validation 
(LOPOCV), resulting in an overall accuracy of 88%. 
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Intra -operative use of Raman spectroscopy 
On the background of these diagnostic capabilities, the group have successfully integrated a 
RS probe into the arm of a robotic system. In a proof of principle study they analysed, in 
vivo, tissue adjacent to the recently excised prostate, which demonstrates the potential for 
clinical application in RS to prostate cancer may not be ex vivo analysis of the excised tissue 











 and thyroid 
145
, but with little further exploration to the application of this 
technology to improving the adequacy of surgical excision margins. In some solid tumour 
pathologies, the use of RS in vivo for the detection of cancer for identification of residual 
tumour and ensuring adequacy of resection is another method of improving surgical 
oncological outcomes.  
In prostate disease, histological studies have differentiated between benign prostatic 
hyperplasia, prostate cancer and normal prostate tissue with a sensitivity of 94% and 
sepecificity of 100%
146
, which was seen to be due to increases in DNA and collagen changes 
in malignancy
147
. In freshly excised tissue both the Fingerprint and HWVN region has been 
used with a hand held probe to get diagnostic accuracy of over 85%
73, 148
. The same group 
have succesfully integrated a RS probe into the arm of a robotic operating system and 
demonstrated the possibility of in vivo surgical guidance to ensure there is no residual disease 
149
. 
There has also been substantial research into the detection of early malignant change in the 
cervix, aided by the well- defined nature of the disease and ability to gain measurements 
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without excision of tissue. Multiple studies have demonstrated the ability of RS to 
differentiate between colposcopically normal and abnormal areas of cervical tissue to a 
clinically relevant degree of accuracy 
150-152
. This may be useful in improving early, accurate 
diagnosis to guide targeted treatment and ensure complete resection of any cervical pre-
cancers. 
 
The ability of RS probes to be incorporated into fibre optics  has significant benefit to the 
potential for use as a surgical adjunct. In bladder cancer fibre optic RS probes have been 
shown to be able to differentiate normal bladder and bladder cancer with an accuracy of 84% 
in pathological samples 
153
. Another group developed a fibre optic probe used in vivo to gain 
measurements at sites within the bladder of 32 patients with suspected bladder cancer that 
were subsequently biopsied and then matched with the definitive histopathological diagnosis. 
These measurements took place alongside fluorescence cystoscopy, a technique already in 
use to improve bladder cancer detection compared to simple white light cystoscopy. This 
clinically relevant technique obtained a sensitivity of 85% and specificity of 79% 
154
. 
The introduction of RS enabled fibre optic probes down working ports in endoscopic 
instruments holds promise for early diagnosis of oesophageal, gastric and colorectal 
pathology, with ex vivo and in vivo studies demonstrating consistently good diagnostic 
accuracy and clinical relevance 
155-158
. The utility of this in achieving adequate surgical 
margins has not been investigated but given the increased risk of recurrence associated with 
involved circumferential resection margins in GI cancers 
159-161
, further work should be 
considered. 
 
Translating Assessment of Raman as to the clinical environment a tool for IMA 
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The ideal method for analysing excised tissueproviding IMA would be sensitive, specific, not 
alter the specimen (to allow subsequent histopathological analysis), recordable to allow 
accountability, give a definitive answer which is easily understood without the need for 
specialist training, and processes the sample without delaying surgery. The tool to deliver the 
analysis should be portable to allow use in multiple locations, robust to withstand everyday 
use, easily sterilised and not interfere with the theatre environment / procedure 
162
.  
In many ways RS meets these criteria. The ability of RS to differentiate between cancer and 
normal tissue in a non destructive manner has been established and appears reliable in a range 
of pathologies. The practical advantages of Raman as a tool for IMA are the relatively cheap 
equipment (£10-30K) is also small and transportable allowing for easy insertion into 
operating theatres. RS systems have been developed that have taken measurements within the 
confines and limitations of the clinical environment, overcoming the obstacles of theatre 
lighting, handling the specimen and the need for a disposable/re-sterilisable component 
126, 
163, 164
, demonstrating its ability to perform in the operating theatre. 
 
Despite these promising advances, RS is still not used in routine clinical practice, suggesting 
limitations to the technique for providing IMA. For effective translation and widespread 
adoption, Raman systems must be cost-effective. The advances in detector technology and 
lower cost lasers resulting in cheaper Raman systems is addressing some of the historical 
short falls in the technique, though it is now the detectors and cameras that account for the 
greatest expense 
165
, systems able to make use of high-quality but mass produced CMOS 
cameras used in mobile phones may be expected to reduce costs significantly.  
 
The time taken to analyse samples remains an issue, however innovative techniques such as 
selective scanning microscopy and SERS has reduced this time and studies presented in this 











review analysed samples in a clinically relevant time frame of 15 – 60 minutes, which is 
within acceptable and clinically relevant limits 
87, 90, 91, 110, 166
. The fact that sample analysis 
can take place within the operating theatre obviously saves significant time compared to 
techniques that require the specimen leaving theatres, such as frozen section analysis.  
though newer techniques beyond spontaneous RS such as selective scanning microscopy and 
SERS has reduced this time.  
 
Thus far, studies have required large data sets with complex and potentially lengthy 
chemometrics to provide accurate diagnostic information. Generally academic teams have 
been gaining spectra for a training set to construct a diagnostic algorithm. This process 
requires a significant amount of data processing and handling with large volumes of data and 
computing power to ‘train’ the diagnostic algorithm, which would be well beyond the 
capabilities of routine clinical staff. However, these are preliminary studies, where the 
diagnostic algorithm is being constructed and tested, but once the diagnostic algorithm has 
been refinedconstructed, robustly tested and acceptedvalidated, the data produced from a 
single specimen for analysis would not be overwhelming. The number of measurements 
required per specimen and the processing power and memory required would obviously be 
dependent on the system, but is very likely to be an affordable cost. The speed of running 
new measurements through a pre-constructed diagnostic algorithm is in the order of 
milliseconds.  
 
?description of data management routines via chemometrics  







When planning for the translation of a technology to the clinical environment, the focus must 
be on the end -user, which for IMA will be surgeons, as they will ultimately determine 
whether the technique is adopted. When using new technologies there can be difficulties with 
inter-user variability- in one study assessing IMA in breast specimens using a bio-impedance 
spectroscopy probe, the results were negatively impacted by the surgeons incorrectly 
following the probe protocol or incorrectly interpretating the results 
167
. Inter-user variability 
may prove particularly problematic for hand held probe systems, where data can be rejected 
or inaccurate due to incorrect probe positioning 
87, 103
. However, there are a range of other 
systems such as an automated tissue processing machine that uses cassettes
111
, or automated 
3D scanner 
166
 that may reduce this potential for user error. 
Not only must the measurements be taken by surgeons, but aA clear and definitive 
interpretation of data is required in order to translate to clinical use. It cannot be expected that 
surgeons should be ablerequired to understand and interpret raw Raman spectra to inform the 
procedure. So far to the authors knowledge, studies in the clinical environment have been in a 
controlled theatre environment with members of the investigating team present to interpret 
Raman spectra. Examples of systems that provide an indicator of the Raman IMA result to 
the surgeon Some systems have been developed to provide an indicator of the Raman IMA 
result to the surgeon, to advance the technique to provide a more clinician friendly output and 
therefore more clinically relevant outcome. Examples of this is the the system work by 
Clemens et al in developing a system capable of emitting a sound to indicate abnormal 
tissues 
168
 and work by Thomas et al. on tthe automated 3D scanner development of a 
‘Marginbot’ which has the potential to analyse a specimen and provide a colour coded 
interpretation of the Raman spectra for the surgeon mapped onto the 3D image of the 






So it can be seen that despite the inevitable challenges in translating from bench to bedside 
(or theatre-side), These techniquesthere are solutions that enable clinical Raman systems 
couldto provide easily interpretable assessmentIMA of surgically excised tissue to aid intra-
operative decision making.  
The technical and logistical aspects of delivering IMA with a RS system need to be 
considered, Figure 5 demonstrates provides some examples of potential existing methods for 
using Raman probes that have the potential to provide for IMA, demonstrating the beginnings 
of successful translation into the clinical environment. Indeed, there are a number of 
companies developing commercially suitable Raman systems showing a move away from the 




A major advantage of Raman is the equipment required is relatively cheap (£10-30K), small 
and is transportable. Indeed, there are a number of companies developing commercially 
suitable Raman systems 
165
. Some groups have already developed systems that have taken 
measurements within the confines and limitations of the clinical environment, overcoming 
the obstacles of theatre lighting, handling the specimen and the need for a disposable/re-
serializable component 
124, 166, 167
, demonstrating its ability to perform in the operating 
theatre. Most of the clinical studies presented in this paper are aware of the need to analyse 
samples in a clinically relevant time frame and this is reported as 15 – 60 minutes depending 
on the technique 
88, 91, 92, 109, 168
. 
 
Despite the advanced stage of some of the Raman systems in use, RS is still not used in 
routine clinical practice, suggesting limitations to the technique. The time taken to analyse 
samples remains an issue, though newer techniques beyond spontaneous RS such as selective 
scanning microscopy and SERS has reduced this time.  
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The advances in detector technology and lower cost lasers resulting in cheaper Raman 
systems is also addressing some of the historical short falls in the technique, though it is now 
the detectors and cameras that account for the greatest expense 
165
, systems able to make use 
of high-quality but mass produced CMOS cameras used in mobile phones may be expected to 
reduce costs significantly.  
A clear and definitive interpretation of data is required in order to translate to clinical use. It 
cannot be expected that surgeons should be able to understand and interpret raw Raman 
spectra to inform the procedure. So far to the authors knowledge, studies in the clinical 
environment have been in a controlled theatre environment with members of the investigating 
team present to interpret Raman spectra. Some systems have been developed to provide an 
indicator of the Raman IMA result to the surgeon, to advance the technique to provide a more 
clinician friendly output and therefore more clinically relevant outcome. Examples of this is 
the work by Clemens et al in developing a system capable of emitting a sound to indicate 
abnormal tissues 
169
 and work by Thomas et al. on the development of a ‘Marginbot’ which 
has the potential to analyse a specimen and provide a colour coded interpretation of the 
Raman spectra for the surgeon mapped onto the 3D image of the specimen 
168
. These 
techniques could provide easily interpretable assessment of surgically excised tissue to aid 




This review has outlined the importance of the optimal management of surgical margins for 
oncological excised specimens, current methods of IMA and a review of the existing 
literature relevant to the use of RS in IMA in a number of solid organ tumour pathologies. It 
must be noted that the majority of RS studies remain in the realms of laboratory work, or 
Field Code Changed
 43 
‘processing labs’ adjacent to theatres with the work performed by members of academic 
units. Protocols have not evolved to the point of being able to be used by non-experts, which 
is crucial to its expansion into the clinical arena. Other disadvantages of RS is the time taken 
for spectral acquisition, though this is being addressed by multimodal techniques 
91
, using the 
HWVN spectra 
141
 or automation of specimen processing 
166
. Ultimately, larger scale clinical 
studies are required to demonstrate the diagnostic accuracy of the technique, and subsequent 
improvement in patient outcomes. As part of this, probes suitable for regular clinical use will 
have to be developed and go through the relevant regulatory processes, and inevitable cost-
effectiveness evaluation. The focus on translation of RS to the clinical environment must 
persist. In an increasingly competitive market of emerging disruptive technologies, future 
studies must focus not only on improvement of outcomes compared to established techniques 
of IMA, but also show relevance amongst novel technologies and techniques. 
 
Despite these hurdles, RS has the ability to provide detailed biochemical information of 
surgical margins with excellent diagnostic accuracy in a range of solid tumour pathologies. 
Further studies are necessary for the translation of this technology to a clinically relevant 
environment and demonstrate improved patient outcomes. RS techniques have the potential 
to provide intra-operative margin analysis of surgically excised solid tumours. 
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Figure 1. A graphic to illustrate the concept of tumour margins. A. A surgically excised 
specimen with an ‘clear’adequate  margins along the resected surface; the cancerous tissue is 
in the centre of the surgically excised specimen, with a rim of normal tissue surrounding it. 
The distance of what defines an ‘adequate’ margin varies between pathologies. B. A 
surgically excised specimen with an inadequate or ‘positive’ margin; the cancerous tissue is 
at the edge of the specimen. This could mean there is further cancerous tissue in the patient 
that has not been excised. 
 
 
Figure 2. A graphical representation of the ideal paradigm for the  surgical workflow of 
intraoperative margin analysis (IMA) by Raman Spectroscopy. This would allow the surgeon 
to remove all cancerous tissue at the initial operation, thus improving patient outcome. 
 
 
Figure 3. Examples of fibre optic probes capable of Raman Spectroscopy measurement in a 
clinical setting for cancer diagnosis, or application to in vivo surgical guidance to provide 
IMA, images Authors own. A. A fibre optic probe is incorporated into a standard 5ml syringe 
with a 15cm long, 20 gauge needle and so is capable of subcutaneous measurements (in this 
example in a Turkey leg) as detailed in reference 
170
. B. A miniature confocal Raman 
packaged probe with a GRIN lens objective for endoscopic use. A detailed review on fibre 




Figure 4. Example of assigning Raman spectra to tissue structures and ductal carcinoma of 
breast tissue to inform the diagnostic algorithm. (a) + (b) invasive ductal carcinoma (IDC), 
(c) normal breast tissue. Red arrows show focus of IDC, green arrow tumour surrounding 
inflammatory stroma, blue arrows  lobules and ducts, black arrows, stroma and orange, fat 
(Reproduced from reference 
57
 K. Kong, F. Zaabar, E. Rakha, I. Ellis, A. Koloydenko and I. 
Towards intra-operative diagnosis of tumours during breast conserving surgery by selective-
sampling Raman micro-spectroscopy. https://doi.org/10.1088/0031-9155/59/20/6141, under a 
Creative Commons Attribution 3.0 licence). 
 
Figure 5. Examples of potential methods for using Raman probe systems that could be useds 
for intraoperative margin analysisIMA using Raman spectroscopy. A. Ex vivo Raman 
spectroscopyRS analysis of a specimen, where the specimen is placed on top of a probe to 
enable a surface to be analysed. This example uses an axillary lymph node (reproduced from 
reference 
172
, with permission from the Royal Society of Chemistry, and the authors) B. 
Design of an automated 3D margin scanner prototype (Marginbot), where the specimen is 
placed on a stage and automated movement of the specimen and the Raman probe (depicted 
by arrows) is required to assess the specimen margins (reproduced from reference 
166
 G. 
Thomas, T. Q. Nguyen, I. J. Pence, B. Caldwell, M. E. O'Connor, J. Giltnane, M. E. Sanders, 
A. Grau, I. Meszoely, M. Hooks, M. C. Kelley and A. Mahadevan-Jansen, Evaluating 
feasibility of an automated 3-dimensional scanner using Raman spectroscopy for 
intraoperative breast margin assessment, https://doi.org/10.1038/s41598-017-13237-y, 
under a creative commons attribution 4.0 International License) C. Handheld probe 
(Emvision, LLC) for use in vivo, in this example to interrogate brain tissue during surgery 
with the potential to assist in gaining clear margins in the excised specimen. The schematic 
diagram illustrates the excitation of different molecular species that produces a Raman 
spectra. From M. Jermyn, K. Mok, J. Mercier, J. Desroches, J. Pichette, K. Saint-Arnaud, L. 
Bernstein, M.-C. Guiot, K. Petrecca and F. Leblond, Sci Transl Med, 2015, 7, 274ra219-
274ra219 
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